Read More 1 minute read News 5 Value Stocks In The Healthcare Sector By Benzinga Insights Today, 8:57 PM The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the… ACRX
Read More 1 minute read News 5 Value Stocks In The Healthcare Sector By Benzinga Insights Today, 8:57 PM What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of… ABOS
Read More 2 minute read Earnings Humacyte’s Return on Invested Capital Insights By Benzinga Insights Today, 8:57 PM Humacyte (NASDAQ:HUMA) brought in sales totaling $31 thousand during Q3 according to data provided by Benzinga Pro. However,… HUMA
Read More 14 minute read Options Stocks That Hit 52-Week Lows On Thursday By Benzinga Insights Today, 8:57 PM On Thursday, 241 companies hit new 52-week lows. ACHL
Read More 8 minute read Options Stocks That Hit 52-Week Lows On Wednesday By Benzinga Insights Today, 8:57 PM On Wednesday, 115 stocks hit new 52-week lows. ALLR
Read More 8 minute read Options Stocks That Hit 52-Week Lows On Thursday By Benzinga Insights Today, 8:57 PM OnThursday, 137 stocks made new 52-week lows. AAP
Read More 5 minute read Options Stocks That Hit 52-Week Lows On Wednesday By Benzinga Insights Today, 8:57 PM On Wednesday, 70 companies set new 52-week lows. AAP
Read More 3 minute read Options Stocks That Hit 52-Week Lows On Tuesday By Benzinga Insights Today, 8:57 PM On Tuesday, 34 companies set new 52-week lows. CHRA
Read More 3 minute read News Humacyte Announces Presentations By Ukrainian Surgeons On Use Of The Human Acellular Vessel To Treat Wartime Vascular Trauma At The European Society For Vascular Surgery Annual Meeting By Benzinga Newsdesk Today, 8:57 PM DURHAM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, complex tissue systems, and HUMA
Read More 1 minute read News Offerings Humacyte Files For Mixed-Securities Shelf Offering Of Up To $300M By Michael Horton Today, 8:57 PM -Reuters HUMA